Why claims data alone cant explain real-world GLP-1 outcomes As adoption accelerates, pharmaceutical companies are racing to innovate through new formulations, delivery options, and combination approaches that improve tolerability and long-term outcomes
What happens when you stop Like all GLP-1 agonist compounds, discontinuing retatrutide results in some weight regain
For instance, GLP-1RA have been tested in people with serious mental illness, who could be at a high suicidality risk, showing metabolic benefits with no increase in psychopathology or occurrence of SIS [22]
10.1016/S2213-8587(24)00318-8 136 StorgaardH.ColdF.GluudL
The clearest contraindications in the FDA labeling are a personal or family history of medullary thyroid carcinoma (MTC), the genetic condition MEN 2, and a known serious allergic reaction to the specific drug
Let's collect some information so we can connect you with the right person.